Aldeyra rises on positive study data for skin disease drug

Aldeyra Therapeutics

19/12/2023 12:31

** Shares of drug developer Aldeyra Therapeutics  ALDX.O  up
7.4% at $3.2 premarket
    ** Co says its experimental drug to treat a type of chronic
skin disease is safe and well tolerated in a small mid-stage
study
    ** Drug candidate ADX-629 also helps reduce disease severity
along a scale that measures severity of eczema symptoms in adult
patients with mild-to-moderate atopic dermatitis (AD) - ALDX 
    ** The trial tested eight mild to moderate patients
suffering from AD, that causes inflammation, redness and
irritation of the skin
    ** Co expects to initiate a placebo-controlled
early-to-mid-stage trial in healthy volunteers and AD patients
in H1'24 and data from the study in H2'24
    ** As of last close, stock down 57.5% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))